Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: The versatile adjuvant for gefitinib therapy

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Lee, Jen Yi ^a,b   Lee, Yee Ming ^a,b   Chang, Gee Chen ^c,d   Yu, Sung Liang ^b   Hsieh, Wan Yu ^a,b   Chen, Jeremy J W ^d   Chen, Huei Wen ^b   Yang, Pan Chyr ^b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^d NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 8; CASPASE 9; CURCUMIN; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE P38; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; SCATTER FACTOR RECEPTOR; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; QUINAZOLINE DERIVATIVE;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IN VITRO STUDY; IN VIVO STUDY; INTESTINE; INTESTINE EPITHELIUM CELL; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MOUSE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SURVIVAL RATE; TUMOR XENOGRAFT; ADENOCARCINOMA; ANIMAL; CELL LINE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; GENETICS; LUNG TUMOR; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE; UBIQUITINATION; WESTERN BLOTTING;

MUS;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CURCUMIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENZYME ACTIVATION; HUMANS; INTESTINES; LUNG NEOPLASMS; MICE; MICE, SCID; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; UBIQUITINATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80051746642     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023756     Document Type: Article

References (62)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
3. Sher T, Dy GK, Adjei AA, (2008) Small cell lung cancer. Mayo Clin Proc 83: 355-367.
4. Perez-Soler R, (2004) HER1/EGFR targeting: refining the strategy. Oncologist 9: 58-67.
5. Kari C, Chan TO, Rocha de Quadros M, Rodeck U, (2003) Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage. Cancer Res 63: 1-5.
6. Levitzki A, (2003) EGF receptor as a therapeutic target. Lung Cancer 41 (Suppl 1): S9-14.
7. Vansteenkiste J, (2004) Gefitinib (Iressa): a novel treatment for non-small cell lung cancer. Expert Rev Anticancer Ther 4: 5-17.
8. Reck M, Gatzemeier U, (2005) Gefitinib ("Iressa"): a new therapy for advanced non-small-cell lung cancer. Respir Med 99: 298-307.
9. Pao W, Miller V, Zakowski M, Doherty J, Politi K, et al. (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101: 13306-13311.
10. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, et al. (2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366: 1527-1537.
11. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139.
12. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500.
13. Wu SG, Chang YL, Hsu YC, Wu JY, Yang CH, et al. (2008) Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern. Oncologist 13: 1276-1284.
14. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, et al. (2005) Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97: 339-346.
15. Engelman JA, Janne PA, (2008) Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 14: 2895-2899.
16. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, et al. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786-792.
17. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, et al. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2: e73.
18. Chen HW, Huang HC, (1998) Effect of curcumin on cell cycle progression and apoptosis in vascular smooth muscle cells. Br J Pharmacol 124: 1029-1040.
19. Chen HW, Yu SL, Chen JJ, Li HN, Lin YC, et al. (2004) Anti-invasive gene expression profile of curcumin in lung adenocarcinoma based on a high throughput microarray analysis. Mol Pharmacol 65: 99-110.
20. Chen HW, Lee JY, Huang JY, Wang CC, Chen WJ, et al. (2008) Curcumin inhibits lung cancer cell invasion and metastasis through the tumor suppressor HLJ1. Cancer Res 68: 7428-7438.
21. Korutla L, Kumar R, (1994) Inhibitory effect of curcumin on epidermal growth factor receptor kinase activity in A431 cells. Biochim Biophys Acta 1224: 597-600.
22. Korutla L, Cheung JY, Mendelsohn J, Kumar R, (1995) Inhibition of ligand-induced activation of epidermal growth factor receptor tyrosine phosphorylation by curcumin. Carcinogenesis 16: 1741-1745.
23. Hong RL, Spohn WH, Hung MC, (1999) Curcumin inhibits tyrosine kinase activity of p185neu and also depletes p185neu. Clin Cancer Res 5: 1884-1891.
24. Chen A, Xu J, Johnson AC, (2006) Curcumin inhibits human colon cancer cell growth by suppressing gene expression of epidermal growth factor receptor through reducing the activity of the transcription factor Egr-1. Oncogene 25: 278-287.
25. Dorai T, Gehani N, Katz A, (2000) Therapeutic potential of curcumin in human prostate cancer. II. Curcumin inhibits tyrosine kinase activity of epidermal growth factor receptor and depletes the protein. Mol Urol 4: 1-6.
26. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, et al. (2001) Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21: 2895-2900.
27. Shishodia S, Chaturvedi MM, Aggarwal BB, (2007) Role of curcumin in cancer therapy. Curr Probl Cancer 31: 243-305.
28. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, et al. (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21: 2237-2246.
29. Cohen MH, Williams GA, Sridhara R, Chen G, McGuinn WD Jr, et al. (2004) United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 10: 1212-1218.
30. Sheng G, Guo J, Warner BW, (2007) Epidermal growth factor receptor signaling modulates apoptosis via p38alpha MAPK-dependent activation of Bax in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 293: G599-606.
31. Duvoix A, Blasius R, Delhalle S, Schnekenburger M, Morceau F, et al. (2005) Chemopreventive and therapeutic effects of curcumin. Cancer Lett 223: 181-190.
32. Lin JK, (2007) Molecular targets of curcumin. Adv Exp Med Biol 595: 227-243.
33. Aggarwal S, Ichikawa H, Takada Y, Sandur SK, Shishodia S, et al. (2006) Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation. Mol Pharmacol 69: 195-206.
34. Kim SY, Jung SH, Kim HS, (2005) Curcumin is a potent broad spectrum inhibitor of matrix metalloproteinase gene expression in human astroglioma cells. Biochem Biophys Res Commun 337: 510-516.
35. Aggarwal BB, Kumar A, Bharti AC, (2003) Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 23: 363-398.
36. Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, et al. (2007) Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res 67: 3853-3861.
37. Aggarwal BB, Sung B, (2009) Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci 30: 85-94.
38. Patel BB, Sengupta R, Qazi S, Vachhani H, Yu Y, et al. (2008) Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R. Int J Cancer 122: 267-273.
39. Kamat AM, Sethi G, Aggarwal BB, (2007) Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through down-regulation of nuclear factor-kappaB and nuclear factor-kappaB-regulated gene products in IFN-alpha-sensitive and IFN-alpha-resistant human bladder cancer cells. Mol Cancer Ther 6: 1022-1030.
40. Howells LM, Mitra A, Manson MM, (2007) Comparison of oxaliplatin- and curcumin-mediated antiproliferative effects in colorectal cell lines. Int J Cancer 121: 175-183.
41. Sung B, Kunnumakkara AB, Sethi G, Anand P, Guha S, et al. (2009) Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model. Mol Cancer Ther 8: 959-970.
42. Giommarelli C, Zuco V, Favini E, Pisano C, Dal Piaz F, et al. (2010) The enhancement of antiproliferative and proapoptotic activity of HDAC inhibitors by curcumin is mediated by Hsp90 inhibition. Cell Mol Life Sci 67: 995-1004.
43. Workman P, Burrows F, Neckers L, Rosen N, (2007) Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann N Y Acad Sci 1113: 202-216.
44. Shimamura T, Lowell AM, Engelman JA, Shapiro GI, (2005) Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. Cancer Res 65: 6401-6408.
45. Sawai A, Chandarlapaty S, Greulich H, Gonen M, Ye Q, et al. (2008) Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel. Cancer Res 68: 589-596.
46. Shimamura T, Li D, Ji H, Haringsma HJ, Liniker E, et al. (2008) Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Res 68: 5827-5838.
47. Gautschi O, Ratschiller D, Gugger M, Betticher DC, Heighway J, (2007) Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation. Lung Cancer 55: 1-14.
48. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043.
49. Arteaga CL, (2007) HER3 and mutant EGFR meet MET. Nat Med 13: 675-677.
50. Seol DW, Chen Q, Zarnegar R, (2000) Transcriptional activation of the hepatocyte growth factor receptor (c-met) gene by its ligand (hepatocyte growth factor) is mediated through AP-1. Oncogene 19: 1132-1137.
51. Li L, Braiteh FS, Kurzrock R, (2005) Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 104: 1322-1331.
52. Thangapazham RL, Puri A, Tele S, Blumenthal R, Maheshwari RK, (2008) Evaluation of a nanotechnology-based carrier for delivery of curcumin in prostate cancer cells. Int J Oncol 32: 1119-1123.
53. Shishodia S, Sethi G, Aggarwal BB, (2005) Curcumin: getting back to the roots. Ann N Y Acad Sci 1056: 206-217.
54. Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG, (2000) Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 6: 4885-4892.
55. Kokubo Y, Gemma A, Noro R, Seike M, Kataoka K, et al. (2005) Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA). Br J Cancer 92: 1711-1719.
56. Judde JG, Rebucci M, Vogt N, de Cremoux P, Livartowski A, et al. (2007) Gefitinib and chemotherapy combination studies in five novel human non small cell lung cancer xenografts. Evidence linking EGFR signaling to gefitinib antitumor response. Int J Cancer 120: 1579-1590.
57. Huang MT, Lysz T, Ferraro T, Abidi TF, Laskin JD, et al. (1991) Inhibitory effects of curcumin on in vitro lipoxygenase and cyclooxygenase activities in mouse epidermis. Cancer Res 51: 813-819.
58. Camacho-Barquero L, Villegas I, Sanchez-Calvo JM, Talero E, Sanchez-Fidalgo S, et al. (2007) Curcumin, a Curcuma longa constituent, acts on MAPK p38 pathway modulating COX-2 and iNOS expression in chronic experimental colitis. Int Immunopharmacol 7: 333-342.
59. Epstein J, Docena G, MacDonald TT, Sanderson IR, (2010) Curcumin suppresses p38 mitogen-activated protein kinase activation, reduces IL-1beta and matrix metalloproteinase-3 and enhances IL-10 in the mucosa of children and adults with inflammatory bowel disease. Br J Nutr 103: 824-832.
60. Song WB, Wang YY, Meng FS, Zhang QH, Zeng JY, et al. (2010) Curcumin protects intestinal mucosal barrier function of rat enteritis via activation of MKP-1 and attenuation of p38 and NF-kappaB activation. PLoS One 5: e12969.
61. Chu YW, Yang PC, Yang SC, Shyu YC, Hendrix MJ, et al. (1997) Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line. Am J Respir Cell Mol Biol 17: 353-360.
62. Chou TC, Talalay P, (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55.